Implanet to Participate at the 2016 BIO CEO Conference in New York

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announced today that management will participate at BIO CEO & Investor Conference 2016 to be held February 8-9, 2016 at the Waldorf Astoria New York.

Ludovic Lastennet, CEO of Implanet will provide an overview of the Company’s operations as he will be available to participate in one-on-one meetings with investors who are registered to attend the conference. BIO CEO & Investor Conference 2016 will have more than 200 publicly-listed and private participating along more than 650 institutional investors registered, coming from across the US and Canada.

• Event: BIO CEO & Investor Conference
• Date: Monday and Tuesday, February 8 and 9, 2016
• Location: Waldorf Astoria; New York

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160203006202/en/